Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MAIA Biotechnology, Inc. (MAIA : AMEX)

• Company Description    MAIA Biotechnology Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of patients with telomerase-positive cancers. MAIA Biotechnology Inc. is based in CHICAGO. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $1.12 Daily Weekly Monthly 20 Day Moving Average: 747,480 shares Shares Outstanding: 32.99 (millions) Market Capitalization: $36.95 (millions) Beta: -0.01 52 Week High: $3.40 52 Week Low: $1.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -26.32% -28.25% 12 Week -29.11% -32.05% Year To Date -43.43% -50.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 444 WEST LAKE STREET SUITE 1700 - CHICAGO,IL 60606 USA ph: 312-416-8592 fax: - ir@maiabiotech.com http://www.maiabiotech.com

• General Corporate Information    Officers Vlad Vitoc - Chief Executive Officer and Chairman Jeffrey C. Himmelreich - Head of Finance Steven Chaouki - Director Ramiro Guerrero - Director Louie Ngar Yee - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 552641102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/20/26 Share - Related Items Shares Outstanding: 32.99 Most Recent Split Date: (:1) Beta: -0.01 Market Capitalization: $36.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.72 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/20/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.76 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -145.45% vs. Previous Quarter: -50.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - -569.99 06/30/25 - -497.29 03/31/25 - -474.86 ROA 09/30/25 - -214.70 06/30/25 - -165.42 03/31/25 - -146.56 Current Ratio 09/30/25 - - 06/30/25 - 2.19 03/31/25 - 2.35 Quick Ratio 09/30/25 - - 06/30/25 - 2.19 03/31/25 - 2.35 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 0.13 03/31/25 - 0.17 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©